Finally, because of the reported overexpression of CXCR4 in AML cells which associates with chemotherapy resistance, LSC development, relapse, and minimal residual disease in AML patients [1–4, 11, 44–47], we believe this nanoconjugate could be used to treat resistant AML. The gene discussed is CXCR4; the disease is acute myeloid leukemia.